The Technology Corner: Disruptive Technology for Prostate Cancer, Part I
In this special series we present emerging technologies which hold the promise to significantly improve the prognosis of patients diagnosed with prostate cancer, and cancer in general. Each day we will showcase a new emerging company, providing an eloquently detailed description of the intriguing technology....
recent news
Written on May 15, 2012
Written on May 15, 2012
Written on May 15, 2012
Written on May 14, 2012
Written on May 10, 2012
Written on May 9, 2012
Katie McHugh and Leon Marucchi of MPR Associates D...
The final interview in our MPR series is with Leon Marucchi, Director of Industrial Design and Katie McHugh, a design engineer at the international consulting firm. Below they discuss concurrent design and design from manufacture and the tremendous value it provides in...
Healthcare’s Digital Revolution: Part I
Just as smartphones are replacing books within the personal realm, electronic tablets are quickly taking the place of paper in doctors’ offices, and are doing so on a global scale.
Healthcare is steadily moving in the direction of digitization, and electronic health...
“Rockstar of Science”, Eric Topol M.D....
Author of “The Creative Destruction of Medicine: How the Digital Revolution Will Create Better Healthcare”, Dr. Eric Topol sits down with OneMedRadio to discuss the ideas and inspiration behind the book. Topol was selected as one of the 12 “Rock Stars of...
The Future of Healthcare: Part II, The Waiting Roo...
In Part II of our expert series on the future of healthcare and The Patient, OneMedPlace sits down with Dr. Cynthia Haines to discuss the digitization of the waiting room.
We are seeing a new push by healthcare providers to better educate patients, and the development...
OneMedForum NY 2012 Sponsor Aptiv Solutions Educat...
Aptiv Solutions is a full-service international CRO with proven expertise in supporting global clinical trials for biopharmaceutical and medical device companies. Their trials span the development lifecycle from first-in-human through regulatory approval and beyond. As...
Compassionate Use of Pluristem’s PLX Cells S...
Pluristem Therapeutics, Inc. (NASDAQCM:PSTI; TASE:PLTR) today announced that a seven year-old girl suffering from an aplastic bone marrow whose condition was rapidly deteriorating is now experiencing a reversal of her condition with a significant increase in her red...
popular news
- Non-Invasive Glucose Monitor Cleared in Europe (16)
- InSound Medical's Lyric: A Long Time Coming (11)
- New Study Highlights Promising Gene-Based Predictor of Prostate Cancer Risk (8)
- NxStage Shares Plummet on Q1 Financial Results (6)
- [Quick Take] Interview with Jeff Rencher, President of Sales & Marketing at Opticon Medical (6)
- Revolution Health Takes on WebMD with User-Centric Focus (5)
- John Kruger: Any one who works with vaccine development knows the potenti...
- Jennifer: Just a matter of a couple of years - at the most, before Adv...
- Jeff Eastman: your readers may be interested inour online computer treatme...
- Harish Kapoor: What is going to be the process for a entrepruner - go to VC...
- Claudio De-Fraja: Three other points could be interesting for Life Science com...
- Larry Gerrans, CEO Sanovas: Crowdfunding is a significant and meaningful opportunity for...
recent from News
The Technology Corner: Disruptive Technology for Prostate Cancer, Part I
In this special series we present emerging technologies which hold the promise to significantly improve the prognosis of patients diagnosed with prostate cancer, and cancer in general. Each day we will showcase a new emerging company, providing an eloquently detailed description of the intriguing technology....
In this special series we present emerging technologies which hold the promise to significantly improve the prognosis of patients diagnosed with prostate cancer, and cancer in general. Each day we will showcase a new emerging company, providing an eloquently detailed description of the intriguing technology....
recent from Research
ADVENTRX Pharmaceuticals Takes the Next Step In Approval of ANX-530
ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX), with its leading innovations in anti-cancer drug development has just announced that they’ve been successful in sending their ANX-530 (Exelbine™) New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) with a Prescription Drug...
ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX), with its leading innovations in anti-cancer drug development has just announced that they’ve been successful in sending their ANX-530 (Exelbine™) New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) with a Prescription Drug...
recent from Profiles
Navigating the Perilous Road: A Special Panel On Regulatory and Reimbursement Issues
The US market represents huge profit potential for an innovative company, but not if unexpected FDA issues impede the launch, or reimbursement issues and adverse patent actions interfere with the success of the product.
Recent studies have indicated that the time to gain approval is dramatically different...
The US market represents huge profit potential for an innovative company, but not if unexpected FDA issues impede the launch, or reimbursement issues and adverse patent actions interfere with the success of the product.
Recent studies have indicated that the time to gain approval is dramatically different...
recent from Video
June 23-24 OneMedForum New York
OneMedPlace Trans-Atlantic Conference on June 23rd-24th is a gathering of fast growing, emerging healthcare and life science companies in Europe and North America.
Its sixth OneMedForum, and second in New York, OneMedPlace will focus on critical success factors for building companies on both sides of the...
